Cidara Therapeutics, Inc. (CDTX) - Dilution Analysis

10-Q filing | 31.4M shares outstanding

10-Q filing | 25.4M shares outstanding

10-Q filing | 14.2M shares outstanding

S-3 filing: The company may offer and sell up to $500,000,000 of any combination of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-K filing | 11.0M shares outstanding

S-1 filing: This S-1 filing registers 7,041,309 shares of common stock for resale by selling stockholders, including 3,892,274 issued and outstanding shares and 3,149,035 shares issuable upon exercise of pre-funded warrants, with the company not receiving any proceeds from the sale.

8-K filing: Cidara Therapeutics, Inc. completed a private placement on November 26, 2024, issuing 3,892,274 shares of common stock and pre-funded warrants to purchase up to 3,149,035 shares of common stock, resulting in gross proceeds of approximately $105.0 million. ($105.0M proceeds)

10-Q filing | 6.5M shares outstanding

10-Q filing | 7.0M shares outstanding

S-1 filing: The filing relates to the offer and resale of up to 16,800,000 shares of common stock by selling stockholders, which are issuable upon conversion of Series A Preferred Stock.

10-Q filing | 4.5M shares outstanding

8-K filing: Cidara Therapeutics entered into a securities purchase agreement for a private placement of 240,000 shares of Series A Convertible Voting Preferred Stock at $1,000 per share, resulting in gross proceeds of $240 million, pending stockholder approval for conversion into common stock. ($240.0M proceeds)

8-K filing: Stock split 1-for-20 | Outstanding: 87,427,439 → 4,371,371

10-K filing | 87.4M shares outstanding

10-Q filing | 90.3M shares outstanding

10-Q filing | 90.1M shares outstanding

10-Q filing | 90.0M shares outstanding

10-K filing | 89.0M shares outstanding

10-Q filing | 70.2M shares outstanding

10-Q filing | 69.1M shares outstanding

10-Q filing | 68.1M shares outstanding

10-K filing | 68.2M shares outstanding

10-Q filing | 66.7M shares outstanding

S-3 filing: The company intends to offer and sell up to $200,000,000 in various securities including common stock, preferred stock, debt securities and warrants.

10-Q filing | 48.7M shares outstanding

10-Q filing | 47.0M shares outstanding

10-K filing | 48.0M shares outstanding

8-K filing: Cidara Therapeutics, Inc. adopted the 2020 Inducement Incentive Plan, reserving 750,000 shares of its common stock for issuance to new employees or returning employees as an inducement to employment.

10-Q filing | 43.2M shares outstanding

10-Q filing | 43.0M shares outstanding

S-3/A filing: This prospectus covers the offer and resale by the selling stockholder identified in this prospectus of up to an aggregate of 4,781,408 shares of our common stock.

S-3 filing: The filing relates to the offer and resale of up to 4,781,408 shares of common stock by a selling stockholder.

10-Q filing | 40.7M shares outstanding

10-K filing | 40.5M shares outstanding